文献速递肿瘤 PET/CT核素与放射性配体治疗

[64Cu][Cu(ATSM)]与离子型Cu(II)盐的乏氧显像及诊疗一体化潜力:现有证据回顾与滞留机制探讨

Hypoxia imaging and theranostic potential of [64Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms.
PubMed 文献 · EJNMMI Res · 2020-04-09

本文综述了铜-64放射性药物([64Cu][Cu(ATSM)]及离子型Cu(II)盐)用于肿瘤乏氧PET显像及治疗的研究证据。临床前与临床研究均显示[64Cu][Cu(ATSM)]具有乏氧选择性,小鼠治疗研究显示剂量依赖性肿瘤体积缩小和生存改善;[64Cu][Cu(ATSM)]与离子型Cu(II)盐在显像和治疗研究中结果相似,支持铜本身在滞留机制中的核心作用。Cu(II)-[Cu(ATSM)]滞留机制仍存争议,未来机制研究应聚焦铜本身在乏氧肿瘤代谢中的作用。

要点

  • [64Cu][Cu(ATSM)]的乏氧选择性已在临床前和临床研究中得到明确证实。
  • 小鼠治疗研究显示剂量依赖性肿瘤体积缩小和生存改善。
  • [64Cu][Cu(ATSM)]与离子型Cu(II)盐在显像和治疗研究中结果相似。

核心结论

  • 铜-64放射性药物用于乏氧肿瘤PET显像和治疗具有前景。
  • Cu(II)-[Cu(ATSM)]滞留机制仍存争议,未来机制研究应聚焦铜本身在乏氧肿瘤代谢中的作用。

研究设计与样本

  • 综述,回顾[60/61/62/64Cu][Cu(ATSM)]及离子型铜盐用于肿瘤乏氧PET显像和治疗的证据,并讨论金属-配体解离机制及基于乏氧下铜代谢研究的铜滞留解释。

主要发现

  • [64Cu][Cu(ATSM)]的乏氧选择性已在临床前和临床研究中得到明确证实。
  • 小鼠临床前治疗研究显示剂量依赖性肿瘤体积缩小和生存改善。
  • Cu(II)-[Cu(ATSM)]似乎蓄积于CD133+表达明显更高的区域,CD133+为癌症干细胞标志物。
  • [64Cu][Cu(ATSM)]与离子型Cu(II)盐在显像和治疗研究中结果相似,支持铜本身在滞留机制中的核心作用。

局限性

  • Cu(II)-[Cu(ATSM)]滞留机制仍存争议。
  • 未来机制研究应聚焦于理解铜本身在乏氧肿瘤代谢中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumor hypoxia (low tissue oxygenation) is an adverse condition of the solid tumor environment, associated with malignant progression, radiotherapy resistance, and poor prognosis. One method to detect tumor hypoxia is by positron emission tomography (PET) with the tracer [64Cu][Cu-diacetyl-bis(N(4)-methylthiosemicarbazone)] ([64Cu][Cu(ATSM)]), as demonstrated in both preclinical and clinical studies. In addition, emerging studies suggest using [64Cu][Cu(ATSM)] for molecular radiotherapy, mainly due to the release of therapeutic Auger electrons from copper-64, making [64Cu][Cu(ATSM)] a "theranostic" agent. However, the radiocopper retention based on a metal-ligand dissociation mechanism under hypoxia has long been controversial. Recent studies using ionic Cu(II) salts as tracers have raised further questions on the original mechanism and proposed a potential role of copper itself in the tracer uptake. We have reviewed the evidence of using the copper radiopharmaceuticals [60/61/62/64Cu][Cu(ATSM)]/ionic copper salts for PET imaging of tumor hypoxia, their possible therapeutic applications, issues related to the metal-ligand dissociation mechanism, and possible explanations of copper trapping based on studies of the copper metabolism under hypoxia. RESULTS: We found that hypoxia selectivity of [64Cu][Cu(ATSM)] has been clearly demonstrated in both preclinical and clinical studies. Preclinical therapeutic studies in mice have also demonstrated promising results, recently reporting significant tumor volume reductions and improved survival in a dose-dependent manner. Cu(II)-[Cu(ATSM)] appears to be accumulated in regions with substantially higher CD133+ expression, a marker for cancer stem cells. This, combined with the reported requirement of copper for activation of the hypoxia inducible factor 1 (HIF-1), provides a possible explanation for the therapeutic effects of [64Cu][Cu(ATSM)]. Comparisons between [64Cu][Cu(ATSM)] and ionic Cu(II) salts have showed similar results in both imaging and therapeutic studies, supporting the argument for the central role of copper itself in the retention mechanism. CONCLUSIONS: We found promising evidence of using copper-64 radiopharmaceuticals for both PET imaging and treatment of hypoxic tumors. The Cu(II)-[Cu(ATSM)] retention mechanism remains controversial and future mechanistic studies should be focused on understanding the role of copper itself in the hypoxic tumor metabolism.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Liu T, Karlsen M, Karlberg AM, et al. Hypoxia imaging and theranostic potential of [64Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms. EJNMMI Res. 2020. PMID: 32274601. doi:10.1186/s13550-020-00621-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。